Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: calcitonin Clear all
Terminated Phase 4 Interventional

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

NCT05492695
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab, Placebo
Drug · Other
Lead sponsor
Diamond Headache Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 26, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet

NCT01329562
View directory record Official record
Conditions
Menstrual Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Springfield, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 26, 2026, 11:24 PM EDT
Terminated Phase 2 Interventional Results available

Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

NCT05142228
View directory record Official record
Conditions
Trigeminal Neuropathy
Interventions
Erenumab-Aooe, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 26, 2026, 11:24 PM EDT
Terminated Phase 2 Interventional Results available

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

NCT03630120
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Poorly Differentiated Thyroid Gland Carcinoma
Interventions
Lenvatinib, Sorafenib, Cabozantinib, Vandetanib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 26, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis

NCT01292187
View directory record Official record
Conditions
Osteopenia
Interventions
Oral calcitonin at dinnertime, Oral placebo at dinnertime, Oral calcitonin at bedtime, Oral placebo at bedtime
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Walnut Creek, California • Clearwater, Florida • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Sep 26, 2026, 11:24 PM EDT
Completed Phase 2 Interventional

Phase II Study of Calcitonin for Tumoral Calcinosis

NCT00004358
View directory record Official record
Conditions
Calcinosis
Interventions
calcitonin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 11:24 PM EDT
Terminated Phase 2 Interventional Results available

Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)

NCT05162027
View directory record Official record
Conditions
Temporomandibular Disorders
Interventions
Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 26, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women

NCT00959764
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Oral Calcitonin Tablets, Intranasal Calcitonin, Placebo tablets and placebo intranasal spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years and older · Female only
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Huntsville, Alabama • Oakland, California • Palm Desert, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 26, 2026, 11:24 PM EDT
Recruiting Phase 4 Interventional

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

NCT03935984
View directory record Official record
Conditions
Primary Hyperparathyroidism, Hypercalcemia
Interventions
Calcitonin
Drug
Lead sponsor
Joseph Sferra
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 26, 2026, 11:24 PM EDT
Completed No phase listed Observational

Pro-Calcitonin Levels Following Pediatric Cardiac Surgery

NCT00284570
View directory record Official record
Conditions
Congenital Heart Disease, Sepsis, Infection
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 5 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 26, 2026, 11:24 PM EDT
Not listed No phase listed Observational

Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.

NCT01609569
View directory record Official record
Conditions
Coronary Disease
Interventions
Not listed
Lead sponsor
Saint Michael's Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Sep 26, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

NCT00525798
View directory record Official record
Conditions
Osteoporosis
Interventions
SMC021 Oral calcitonin, SMC021 Placebo
Drug
Lead sponsor
Nordic Bioscience A/S
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
4,665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Gainesville, Georgia • Detroit, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 26, 2026, 11:24 PM EDT
Completed Not applicable Interventional Results available

Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

NCT00478335
View directory record Official record
Conditions
Nephrogenic Diabetes Insipidus
Interventions
sildenafil, calcitonin, hydrochlorothiazide/amiloride, indomethacin, Placebo for sildenafil, placebo for calcitonin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 25 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 26, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

NCT02621931
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
179
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 26, 2026, 11:24 PM EDT
Completed Not applicable Interventional

RecoveryPlus Telerehab Platform Pilot Study

NCT05804500
View directory record Official record
Conditions
Heart Diseases, Angina, Stable, Angina Pectoris, Myocardial Ischemia, Myocardial Infarction, Coronary Artery Disease, Coronary Artery Stenosis, Valve Heart Disease, Valve Disease, Heart
Interventions
Cardiac Telerehabilitation (CTR) via the RecoveryPlus platform
Behavioral
Lead sponsor
NODEHealth Foundation
Other
Eligibility
45 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Sep 26, 2026, 11:24 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

New Daily Persistent Headache Biomarkers Study

NCT04260087
View directory record Official record
Conditions
New Daily Persistent Headache, New Daily Persistent Headache (NDPH)
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 26, 2026, 11:24 PM EDT
Not yet recruiting Not applicable Interventional

STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection

NCT07612293
View directory record Official record
Conditions
Thyroid Gland Medullary Carcinoma
Interventions
Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan, Neck Dissection, Surveillance, Thyroid Lobectomy, Thyroidectomy, Ultrasound Imaging
Procedure · Behavioral
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 26, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients

NCT03898856
View directory record Official record
Conditions
Chronic Diarrhea of Unknown Origin
Interventions
Crofelemer, Diagnostic tests for cause of chronic diarrhea
Drug · Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 26, 2026, 11:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia

NCT05895500
View directory record Official record
Conditions
Dry Eye, Asthenopia
Interventions
Injection for SC administration (120mg/syringe), Tablet (50mg/tablet), oral
Drug
Lead sponsor
Nvision Laser Eye Centers
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 26, 2026, 11:24 PM EDT